General Lung Cancer

Lung Cancer Advances: Precision Medicine and Immunotherapy Make a Difference (March 1, 2016)

Precision medicine continues to impact the lives of lung cancer patients with research into genomics and genetics leading to unprecedented progress in improving outcomes. Tailored treatments have emerged... Continue Reading

Immune-Targeting Drug Combo Shows Promise for Non-Small Cell Lung Cancer Patients, Say Moffitt Cancer Center Researchers (February 22, 2016)

Lung cancer is the most common cause of cancer-related deaths in the United States resulting in more than 158,000 deaths each year. With a 5-year survival rate at only 18 percent, the development of new... Continue Reading

Alecensa™ Approved for the Treatment of Recurrent ALK-Positive Lung Cancer (December 24, 2015)

The FDA approved another inhibitor of anaplastic lymphoma kinase (ALK) for treatment of non-small cell lung cancer (NSCLC) today, further expanding precision treatment options. Alecensa™ (Alectinib)... Continue Reading

Alectinib Produces High Anti-Cancer Activity in Recurrent Lung Cancer (December 3, 2015)

The investigative agent, alectinib, produces high anti-cancer responses among patients with non-small cell lung cancer (NSCLC) that have stopped responding to Xalkori™(crizotinib). These results were... Continue Reading

Novel Precision Medicine Tagrisso Approved for Treatment of Lung Cancer (November 19, 2015)

The United States Food and Drug Administration (FDA) has approved Tagrisso (osimertinib) for the treatment of lung cancer with the epidermal growth factor receptor (EGFR) T790M mutation. The indication... Continue Reading

New Lab Test Enables Precision Treatment for Lung Cancer (November 13, 2015)

The complementary laboratory test that measures PD-L1 levels among patients with lung cancer who are to receive treatment with Opdivo® (nivolumab), is now available for commercial use and can help guide... Continue Reading

Updated Results Confirm Improved Survival with Opdivo® in Lung Cancer (November 10, 2015)

Longer follow-up confirms the survival benefit with the use of the PD-1 inhibitor, Opdivo® (nivolumab), compared to the chemotherapy agent, docetaxel, among patients with recurrent non-small cell lung... Continue Reading

Opdivo® Receives Expanded Approval for an Additional Type of Lung Cancer (October 19, 2015)

The United States Food and Drug Administration (FDA) has expanded the approval of Opdivo® (nivolumab) for the treatment of non-squamous, non-small cell lung cancer. Non-small cell lung cancer (NSCLC),... Continue Reading

FDA Approves Keytruda® for Lung Cancer (October 13, 2015)

The programmed death (PD-1) inhibitor Keytruda® (pembrolizumab) has been granted approval by the US Food and Drug Administration (FDA) for use in lung cancer, becoming the first PD-1 inhibitor and the... Continue Reading

Iressa® Approved as Initial Therapy for Lung Cancer (September 23, 2015)

The targeted agent Iressa (gefitinib) has been approved by the U.S. Food and Drug Administration (FDA) as initial therapy in the treatment of patients with advanced lung cancer. Specifically, Iressa was... Continue Reading

Gilotrif Improves Outcomes in Lung Cancer (September 22, 2015)

The targeted agent Gilotrif (afatinib) improves outcomes compared to Tarceva (erlotinib) among patients with squamous cell lung cancer. These results were recently published in The Lancet Oncology. Lung... Continue Reading

FDA Grants Alectinib Priority Review for ALK-Positive Lung Cancer (September 15, 2015)

The U.S. Food and Drug Administration (FDA) has granted Priority Review for alectinib, an oral anaplastic lymphoma kinase (ALK) inhibitor, for the treatment of people with ALK-positive, non-small cell... Continue Reading

Early Results of Opdivo® Combined with Yervoy® Presented at 16th World Conference on Lung Cancer (September 14, 2015)

An early-stage study shows Opdivo® (nivolumab) treatment can be safely and effectively paired with relatively low and infrequent dosages of Yervoy® (ipilimumab) immunotherapy for patients with previously... Continue Reading

Updated Trial Results Demonstrating Benefit of Opdivo® Released at the 16th World Conference on Lung Cancer (September 10, 2015)

Results from the CheckMate -017 and -063 clinical trials evaluating Opdivo® (nivolumab) in previously treated squamous cell non-small cell lung cancer (NSCLC) were released today at the 16th World Conference... Continue Reading

16th World Conference on Lung Cancer Expected to Highlight Advances in Precision Medicine (September 6, 2015)

Today, September 6, the 16th World Conference on Lung Cancer (WCLC) begins in Denver, Colorado. The WCLC is the world’s largest meeting dedicated to lung cancer and other thoracic malignancies. More... Continue Reading

Afinitor® Promising in Neuroendocrine Tumors Originating in Gastrointestinal Tract or Lungs (August 10, 2015)

The drug Afinitor® (everolimus) is currently be studied in a Phase III clinical trial for patients with nonfunctional neuroendocrine tumors (NET) of the gastrointestinal (GI) tract or lungs. The trial... Continue Reading

FDA Approves Iressa for Treatment of Patients with Metastatic Non Small Cell Lung Cancer (July 20, 2015)

The U. S. Food and Drug Administration approved IRESSA (gefitinib) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR)... Continue Reading

Aetna Provides Coverage for Biodesix’ VeriStrat Test (June 25, 2015)

Biodesix, Inc. announced that its VeriStrat® test is now considered a medically necessary benefit by Aetna Corporation (NYSE: AET).  Aetna published a positive coverage policy for the VeriStrat proteomic... Continue Reading

« Previous PageNext Page »

Sign up for the CancerConnect newsletter

Sign up for our newsletter and receive the latest news and updates about specific types of cancer.

  Close |  Please don't show me this again

Facebook Twitter RSS